The Interpretation of Clinical Exome or ICE Project is a collaborative effort led by IntegraGen to develop an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients.

The objective of the ICE Project is to optimize the diagnosis of cancer patients and to develop a data driven approach for identifying targeted treatment options for these patients base on exome and transcriptome sequencing data. The collaborators for the project include IntegraGen, Gustave Roussy, the leading European center in the fight against cancer in Europe, Sogeti High Tech, a 100% subsidiary of the Capgemini Group, and INSERM.

The ICE Project was selected as part of the call for proposals for the 17th Single Interministerial Fund (Fonds Unique Interministériel). The four project partners bring unique experiences in oncology, sequencing, data management, software development and clinical interpretation of sequencing data. As a result of this funding, the partners anticipate the rapid development of the first version of this software tool.

The partners for the ICE Project plan to finalize a first version of the software tool in 2017.


“The exponential growth in the availability of sequencing data from the tumors of cancer patients has created a need to develop tools that permits the isolation of patient specific data with the associated identification of information which impacts the clinical care of patients. Access to sequencing data of all coding genes of a patient requires a thorough review of the sequencing results and automated assistance its interpretation, otherwise the data will not be usable or compatible with the timely management of cancer patients.

– Professor Eric Solary, Research Director, Gustave Roussy

“Genomic sequencing has been revolutionized by the advent of newer technologies that utilize massively parallel sequencing in order to greatly reduce the cost and time of data generation. As a result, the bottleneck is now the management of tens of gigabytes of data that represent the exome and transcriptome of a patient’s  tumor. The ICE Project will allow clinicians to treat patients according to the biological characteristics of their tumor.”

– Dr. Bernard Courtieu, Chairman and CEO, IntegraGen